News25/Ratings0
News · 26 weeks61-46%
2026-04-192026-10-11
Mix2690d
- SEC Filings11(42%)
- Other8(31%)
- Insider5(19%)
- Leadership1(4%)
- Market1(4%)
Latest news
25 items- SECSEC Form 424B3 filed by Medicus Pharma Ltd.424B3 - Medicus Pharma Ltd. (0001997296) (Filer)
- SECSEC Form 8-K filed by Medicus Pharma Ltd.8-K - Medicus Pharma Ltd. (0001997296) (Filer)
- PRMedicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term ValuePHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today provided a shareholder update celebrating its third anniversary, highlighting three years of progress, focused on execution and capital efficient drug development. The Company has advanced its transformation into a precision oncology-led biotechnology company, with a portfolio of select novel assets, anchored by CD228V, an investigational antibody-drug conjugate molecule utilizing Pfizer’s established vedotin linker-payload platform, SkinJect for basal
- SECSEC Form 424B3 filed by Medicus Pharma Ltd.424B3 - Medicus Pharma Ltd. (0001997296) (Filer)
- SECSEC Form 8-K filed by Medicus Pharma Ltd.8-K - Medicus Pharma Ltd. (0001997296) (Filer)
- PRMedicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate CancerPHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that it has submitted an optimized seamless Phase 2b/3 registration-intent protocol to the U.S. Food and Drug Administration ("FDA") for Teverelix®, its investigational, next generation, long-acting GnRH antagonist, in advanced prostate cancer ("APC") patients at increased cardiovascular ("CV") risk. The submission is designed to establish a defined, capital-efficient and partner-ready registrational pathway for Teverelix without Medicus in
- PRMedicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory AssessmentPHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that it will focus future internally sponsored clinical development of SkinJect® exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and conclude further development in sporadic/nodular basal cell carcinoma ("nBCC"). The decision represents a further implementation of the Company’s capital-efficient portfolio strategy announced on September 8, 2026, under which Medicus is concentrating capital and organization
- SECSEC Form SCHEDULE 13D filed by Medicus Pharma Ltd.SCHEDULE 13D - Medicus Pharma Ltd. (0001997296) (Subject)
- SECSEC Form 424B3 filed by Medicus Pharma Ltd.424B3 - Medicus Pharma Ltd. (0001997296) (Filer)
- SECMedicus Pharma Ltd. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits8-K - Medicus Pharma Ltd. (0001997296) (Filer)
- SECMedicus Pharma Ltd. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Medicus Pharma Ltd. (0001997296) (Filer)
- PRMedicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development DosePHILADELPHIA, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that an abridged Clinical Study Report (CSR) for SKNJCT-003 (NCT06608238) has been posted on ClinicalTrials.gov, providing transparent public access to the efficacy, safety, drug-delivery and clinical findings from the completed Phase 2 study. Publication of the abridged CSR represents an important scientific milestone for SkinJect® and provides a transparent public record of the completed Phase 2 findings. The Company believes the dataset
- INSIDERChief Operating Officer Smith Andrew Alasdair was granted 735,294 shares, increasing direct ownership by 448,350% to 735,458 units (SEC Form 4)4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERChief Medical Officer Mehmud Faisal was granted 1,470,588 shares (SEC Form 4)4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERChief Scientific Officer Brennan Edward J. was granted 588,235 shares, increasing direct ownership by 680% to 674,735 units (SEC Form 4)4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERPresident and CFO Bonner Carolyn F. was granted 1,470,588 shares, increasing direct ownership by 7,779% to 1,489,493 units (SEC Form 4)4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERChief Executive Officer Bokhari Raza was granted 2,941,176 shares (SEC Form 4)4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- PRMedicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology CompanyPHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today provided a strategic update highlighting its transformation into a precision oncology-led biotechnology company, anchored by the advancement of CD228V, a second-generation CD228-targeted antibody-drug conjugate ("ADC"), while pursuing capital-efficient strategic partnerships to advance clinical development opportunities across its SkinJect® and Teverelix® Programs. CD228V now represents the principal strategic prio
- SECSEC Form 424B3 filed by Medicus Pharma Ltd.424B3 - Medicus Pharma Ltd. (0001997296) (Filer)
- SECMedicus Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Medicus Pharma Ltd. (0001997296) (Filer)
- SECSEC Form 424B3 filed by Medicus Pharma Ltd.424B3 - Medicus Pharma Ltd. (0001997296) (Filer)
- NEWSMedicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateCompany Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion PHILADELPHIA, PA / ACCESS Newswire / August 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today reported financial results for the three and six months ended June 30, 2026, and provided a corporate update highlighting significant regulatory, clinical and strategic achievements across its development portfolio.During th
- SECSEC Form 10-Q filed by Medicus Pharma Ltd.10-Q - Medicus Pharma Ltd. (0001997296) (Filer)
- PRMedicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United KingdomPHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the appointment of Faisal Mehmud, MD, MRCP, as Chief Executive Officer of Antev Limited, United Kingdom ("Antev"), the Company’s United Kingdom subsidiary, effective August 30, 2026. Dr. Mehmud will continue to serve as Chief Medical Officer of Medicus and Co-Chairman of Antev providing unified scientific, clinical, regulatory and operational leadership as the Company advances the global development of Teverelix® across mu
- PRMedicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with EndometriosisPHILADELPHIA, July 31, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that the United Arab Emirates (UAE) Department of Health – Abu Dhabi ("DOH") has granted Investigational New Drug ("IND") authorization for the Company's PRECISION-E2 Phase 2a clinical study evaluating Teverelix® in women with moderate-to-severe symptomatic endometriosis, a chronic estrogen-dependent inflammatory disease that affects approximately one in ten women of reproductive age worldwide. The authorization follows co
MDCX FAQ
4 questionsWhere does MDCX stock trade?
Medicus Pharma Ltd. (MDCX) is listed on NASDAQ.What sector and industry is MDCX in?
Medicus Pharma Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to MDCX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MDCX side-by-side with any of them on Quantisnow.How can I track MDCX on Quantisnow?
Quantisnow aggregates Medicus Pharma Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDCX to receive live email and push alerts on every new disclosure.